Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials by Wagner, A D et al.
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and
gallbladder carcinoma: two parallel, multicentre phase-II trials
AD Wagner*,1,8, P Buechner-Steudel
1, M Moehler
2, H Schmalenberg
3, R Behrens
4, J Fahlke
5, A Wein
6,
S Behl
1, O Kuss
7, G Kleber
1,9 and WE Fleig
1,10
1First Department of Medicine, University Hospital, Halle 06097 (Saale), Germany;
2First Department of Medicine, University Hospital, Mainz 55131,
Germany;
3Department of Medicine II, University Hospital, Jena 07740, Germany;
4Gastroenterology Practice, Halle 06108 (Saale), Germany;
5Department of Visceral Surgery, University Hospital, Magdeburg 39120, Germany;
6First Department of Medicine, University Hospital, Erlangen 91054,
Germany;
7Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Halle 06097 (Saale), Germany
BACKGROUND: Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer and have a potentially synergistic
mode of action and non-overlapping toxicity. The objective of these trials was to determine response, survival and toxicity separately
in patients with bile duct cancer (BDC) and gallbladder cancer (GBC) treated with gemcitabine/oxaliplatin/5-FU chemotherapy.
METHODS: Eligible patients with histologically proven, advanced or metastatic BDC (n¼37) or GBC (n¼35) were treated with
gemcitabine (900mgm
 2 over 30min), oxaliplatin (65mgm
 2) and 5-FU (1500mgm
 2 over 24h) on days 1 and 8 of a 21-day
cycle. Tumour response was the primary outcome measure.
RESULTS: Response rates were 19% (95% CI: 6–32%) and 23% (95% CI: 9–37%) for BDC and GBC, respectively. Median survivals
were 10.0 months (95% CI: 8.6–12.4) and 9.9 months (95% CI: 7.5–12.2) for BDC and GBC, respectively, and 1- and 2-year survival
rates were 40 and 23% in BDC and 34 and 6% in GBC (intention-to-treat analysis). Major grade III and IV adverse events were
neutropenia, thrombocytopenia, elevated bilirubin and anorexia.
CONCLUSION: Triple-drug chemotherapy achieves comparable results for response and survival to previously reported regimens, but
with more toxicity.
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Although biliary tract cancer (BTC) is a rare cancer in Europe and
North America, there is substantial geographical variation, with
high mortality rates in Central and Eastern Europe, Japan, India,
Korea and Shanghai (China). The highest rates of up to 16.6/
100000 women are seen in Chile (Randi et al, 2009). Biliary tract
cancer includes gallbladder cancer (GBC) and bile duct cancer
(BDC). Bile duct cancer may be further subdivided into
intrahepatic cholangiocarcinoma and adenocarcinoma of the
extrahepatic bile ducts, which includes Klatskin’s tumours at the
liver hilus. Unfortunately, fewer than 10% of all patients are
candidates for curative resection, and relapse rates remain high
after surgery (Hezel and Zhu, 2008). Thus, systemic chemotherapy
is given to the majority of patients.
Compared with best supportive care, fluoropyrimidine-based
combination chemotherapy has been shown in a randomised trial
to improve survival and quality of life (QoL) in bilio-pancreatic
cancer (Glimelius et al, 1996).
Bile duct cancer is a heterogeneous group with increasing
evidence of differences between BDC and GBC at both clinical
(Yonemoto et al, 2007) and molecular levels (Jarnagin et al, 2006).
A recently published, pooled analysis of 104 chemotherapy trials in
BTC identified response rates of 34.4 and 20.2%, respectively, in
patients with GBC and BDC (Eckel and Schmid, 2007). Despite the
significantly better response rate in GBC, patients with GBC had a
shorter median overall survival (7.2 months) than those with BDC
(9.3 months; P¼0.048). This observation was confirmed by a large
(n¼413), retrospective analysis from Japan reporting a median
survival of 8.4 months (95% CI: 5.5–11.2) for intrahepatic
cholangiocarcinoma, 10.2 months (95% CI: 5.4–13.7) for extra-
hepatic BDC and 6.5 months (95% CI: 5.3–8.0) for GBC
(Yonemoto et al, 2007). In addition, several individual trials
including patients with both BDC and GBC have reported clinically
important differences between BDC and GBC, ranging from 2.7
to 12.4 months (Sanz-Altamira et al, 1998; Patt et al, 2001;
Alberts et al, 2005; Knox et al, 2005; Kobayashi et al, 2006) in
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patients. In a randomised phase II trial, which compared a
combination of 5-fluorouracil (5-FU)/cisplatin chemotherapy with
single-agent 5-FU chemotherapy in BTC, the response rates and
median overall survival tended to be superior with the doublet
(18.5 vs 7.1% and 8.0 vs 5.0 months, respectively); however, the
differences were not statistically significant (Ducreux et al, 2005).
Significantly better response rates (24 vs 15%) and survival (8.3 vs
11.7 months, P¼0.002) for the gemcitabine/cisplatin combination
– as compared with single-agent gemcitabine – have been reported
in the recently presented landmark trial UK ABC-02, which is the
largest randomised study in BTC to date (Valle et al, 2009).
Although results from randomised trials comparing the combina-
tion of gemcitabine and 5-FU in BTC are lacking, the available data
for the combination of gemcitabine and fluoropyrimidines in
pancreatic cancer are controversial. Although the gemcitabine/5-
FU combination has no advantage in survival when compared with
gemcitabine alone (Riess et al, 2005), a randomised phase III trial
comparing gemcitabine/capecitabine vs gemcitabine alone showed
a significant survival benefit for the two-drug combination (HR for
survival 0.8; 95% CI: 0.65–0.98; P¼0.026) (Cunningham et al,
2005). Whether treatment results for biliary cancer might be
further improved using three-drug combinations is still unclear.
On the basis of the evidence of their activity in BTC (Eckel and
Schmid, 2007), their non-overlapping toxicity profiles and a
potentially synergistic mode of action (Peters et al, 1995; Faivre
et al, 1999), we investigated the efficacy and safety of the triplet
combination of gemcitabine, oxaliplatin and infusional 5-FU
(GemFOx) in patients with locally advanced or metastatic BDC
and GBC.
Separation of the patients into two parallel but separate
phase II trials for BDC and GBC was motivated by both, their
different prognosis and potentially different response to
chemotherapy.
PATIENTS AND METHODS
Eligibility criteria
Eligible patients met the following criteria: histologically con-
firmed, unresectable, locally advanced (UICC stage III, T1–4 and
N1), metastatic (UICC stage IV, T1–4,N 1 and M1) or recurring
(after resection) adenocarcinoma of the bile ducts (BDC study)
or gallbladder (GBC study); bidimensionally measurable tumour
lesion; age 18–75 years; ECOG status 0–1; estimated life
expectancy of X3 months; and adequate bone marrow function
(white blood cell count X3.5 10
9/l, platelets X100 10
9/l).
Adjuvant chemotherapy or radiation therapy was permitted if it
had been terminated at least 6 months before the inclusion in this
trial. Exclusion criteria were borderline tumours, serious comorbid
conditions, bilirubin X1.5 times the upper limit of normal (ULN)
despite adequate endoscopic biliary drainage, alanine amino
transaminase (ALT) and aspartate amino transaminase (AST)
levels 45 and 2.5 times, respectively, the ULN in patients with and
without liver metastases, creatinine exceeding 200mmoll
 1,
pregnancy and lactation, earlier chemotherapy, suspected cerebral
metastases and peripheral sensory neuropathy. The studies
were conducted in accordance with the Declaration of Helsinki
Principles and Good Clinical Practice guidelines. Supportive
care measures such as antibiotic therapy and administration of
haematopoietic growth factors were permitted and used at the
discretion of the investigator. Written informed consent was
obtained from all patients before entering the study. The
Ethics Committee of the Medical Faculty (Martin-Luther-
University Halle-Wittenberg, Germany) and the responsible ethics
committees for the participating institutions had approved the
protocol.
Study design and treatment
These single-arm, multicentre phase II studies were conducted in
parallel at the same institutions. The study protocol was approved
and supported by the Arbeitsgemeinschaft Internistische
Onkologie (AIO). Similar to our parallel phase II study in
pancreatic cancer (Wagner et al, 2007), patients were treated with
gemcitabine (900mgm
 2 as a 30-min infusion), followed by
oxaliplatin (65mgm
 2 as a 2-h infusion) and 5-FU (1500mgm
 2
without folinic acid as a 24-h continuous infusion), all on days 1
and 8 of a 21-day schedule. Treatment was terminated on disease
progression or unacceptable toxicity, or at the patient’s or
investigator’s request. Drug doses were modified on the basis of
blood counts taken before each administration to maintain a
tolerable safety profile. Treatment was interrupted as soon as
leukopenia or diarrhoea of 4grade I or any other toxicity (except
alopecia) of 4grade II was observed. If time to recovery from any
toxicity was more than 1 week, subsequent doses were reduced to
80%. In case of sensory neuropathy lasting longer than 7 days,
oxaliplatin was administered at 80% of the initial dose in
subsequent cycles. When functional impairment attributed to
sensory neuropathy was not relieved at the time of the next
scheduled administration, treatment with oxaliplatin was withheld
until recovery.
Assessment
Pretreatment evaluations consisted of a complete medical history,
physical examination, assessment of ECOG status, blood count,
blood chemistry including CA 19-9 and urine analysis. Tumour
measurements were performed with either computerised tomo-
graphy or magnetic resonance imaging every 6 weeks, with tumour
responses classified according to the WHO criteria (Miller et al,
1981). Blood counts were obtained before each chemotherapy
administration, and serum chemistry and urine analysis were
carried out before each new cycle. Toxicity was classified
according to the NCI-CTC (version 2.0). Quality of life was
assessed before therapy and after every two cycles using the FACT-
Hep questionnaire (Heffernan et al, 2002). After discontinuation of
treatment, follow-up was scheduled every 3 months.
Statistical methods and analysis
According to the study protocol, three populations for analysis
were defined as follows:
1. Safety population: All patients who received the study
medication at least once.
2. Intention-to-treat (ITT) population: All eligible patients who
received the study medication at least once.
3. Per-protocol (PP) population: All patients who completed at
least two cycles of chemotherapy.
Objective response rate as the primary end point of both studies
was assessed in both the PP and ITT populations. The secondary
end points – median overall survival, time to progression (TTP)
and 1- and 2-year overall survival rates – were analysed in the ITT
population only. On the basis of the results published for single-
agent therapy with gemcitabine (Valle et al, 2009), we predefined
overall response rates of 10 and 30% in the PP population as being
clinically irrelevant and relevant, respectively. The sample size
necessary for the primary end point was calculated accepting a
type I error of 5% and a test power of 90%. This resulted in a target
enrolment of 35 response-evaluable patients in each study. Time to
progression and survival were analysed using standard methods of
survival analysis. Survival function was estimated by the Kaplan–
Meier method (Kaplan and Meier, 1958). Response rates, median
survival times and survival rates are given with 95% CIs.
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Patients and treatment
A total of 38 patients with BDC and 37 patients with GBC were
enrolled between February 2002 and October 2004. Follow-up was
performed until death or up to a maximum of 60 months. Patient
flow is depicted in Figure 1. Baseline demographic and clinical
characteristics of the ITT and PP populations are summarised in
Table 1. In the BDC study, a total of 299 cycles of study therapy
were started and 280 cycles completed. The median number of
cycles per patient was 6.0 (range: 1–28). In the GBC study, a total
of 274 treatment cycles were started and 265 completed. The
median number of cycles per patient was 8 (range: 0–18).
Efficacy
Objective response rates in both the PP and ITT populations are
presented in Table 2. No patient in either study showed a complete
response and none of the patients with a partial response qualified
for secondary resection. The Kaplan–Meier curves for overall
survival of the ITT populations in both trials are depicted in
Figure 2.
BDC trial On ITT analysis, median overall survival and time
to progression were 10.0 (95% CI: 8.6–12.4) and 6.2 (95% CI:
5.1–11.5) months, respectively. One- and 2-year overall survival
rates were 40% (95% CI: 25–56%) and 23% (95% CI: 11–38%),
respectively.
GBC trial On ITT analysis, median overall survival and time to
progression were 9.9 (95% CI: 7.5–12.2) and 5.7 (95% CI: 3.1–8.1)
months, respectively. One- and 2-year overall survival rates were
34% (95% CI: 20–51%) and 6% (95% CI: 1–16%), respectively.
The pooled results for QoL from both studies, as measured
by the FACT-Hep questionnaire, are depicted in Figure 3. Overall,
the FACT-Hep global score in those patients who completed the
questionnaires remained stable over the treatment period.
However, these data should be interpreted with great caution
because of a significant number of missing questionnaires. Bias
attributed to the selective return of questionnaires from patients in
good performance status cannot be excluded for this reason.
Adverse events
The most common adverse events, rated by the attending
physician as NCI-CTC grade I–IV, are reported in Table 3.
Treatment was well tolerated in the majority of patients. Most
patients in both trials discontinued study therapy because of
disease progression or deteriorating performance status. There
were no treatment-related deaths.
Bile duct cancer study  Gallbladder cancer study 
Included patients (n = 38)
1 patient excluded
because histology was 
not confirmed (n = 1)
Safety population: All
patients who received the 
study medication at least 
once (n = 38)
3 patients excluded 
because of 
￿ rapid  disease 
progression (n = 1)
￿ early  death  (n = 1)
￿ insufficient  staging   
(n = 1)
PP population: All patients 
who completed at least two 
cycles of chemotherapy
(n = 34)
ITT population: All eligible 
patients who received the 
study medication at least 
once (n = 37)
1 patient excluded
(ineligible because of 
high bilirubin, never 
received study 
therapy) (n = 1)
Included patients (n = 37)
1 patient excluded
because histology was 
not confirmed (n = 1)
Safety population: All
patients who received the 
study medication at least 
once (n = 36)
4 patients excluded 
because they did not 
complete two cycles of 
therapy because of rapid 
deterioration of 
performance status
(n = 4)
PP population: All patients 
who completed at least two 
cycles of chemotherapy
(n = 31)
ITT population: All eligible 
patients who received the 
study medication at least 
once (n = 35)
Figure 1 Diagram of patient flow.
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12 were obstructive jaundice requiring endoscopic treatment. One
patient each experienced deep venous thrombosis and pulmonary
embolism. All serious adverse events except one were regarded as
unrelated to therapy by the investigators. One patient with a history of
cardiomyopathy suffered sudden death 1 day after the administration
of chemotherapy. Whether this event was related to the underlying
disease, 5-FU-associated cardio toxicity or both is not clear. A total of
21 hospitalisations were necessary in BDC patients; among these, 9
were attributable to febrile infections, mostly cholangitis (8 patients).
One patient in this group had febrile neutropenia.
Chemotherapy was administered as planned for 55.3% of
scheduled treatments. Dosage had to be reduced for 20% or
treatment deferred for 15%, or both for 7.8%, of scheduled
administrations. In one patient, therapy was discontinued because
of an allergic reaction to oxaliplatin.
GBC trial A total of 19 serious adverse events occurred. Only one
of these (dysphagia and sustained vomiting with onset soon after
the administration of chemotherapy) was considered as possibly
related to the study therapy by the investigator. Most other serious
adverse events were rated as associated with the underlying
Table 1 Baseline characteristics
BDC study GBC study
ITT population PP population
a ITT population PP population
b
Number of patients 37 34 35 31
Age (years)
Median 61.5 61.7 64.1 63.9
Range 36.1–75.9 38.3–74.8 42.6–79.8 42.6–79.8
Gender, n (%)
Male 17 (46) 16 (47) 10 (29) 9 (29)
Female 20 (54) 18 (53) 25 (71) 22 (71)
ECOG status, n (%)
Median 0 0 0 0
0 24 (65) 24 (71) 25 (71) 22 (71)
1 12 (32) 10 (29) 10 (29) 9 (29)
Disease status, n (%)
Locally advanced 8 (22) 7 (21) 3 (9) 3 (10)
Metastatic 29 (78) 27 (79) 32 (91) 28 (90)
Number of organs with metastases, n (%)
0 4 (11) 4 (12) 1 (3) 1 (3)
1 17 (46) 16 (47) 13 (37) 12 (39)
2 9 (24) 7 (21) 16 (46) 14 (45)
3 5 (14) 5 (15) 2 (6) 1 (3)
43 2 (5) 2 (6) 3 (9) 3 (10)
Recurrence after prior surgical resection, n (%) 15 (41) 14 (41) 10 (29) 9 (29)
Abbreviations: BDC¼bile duct cancer; GBC¼gallbladder cancer; ITT population¼intention-to-treat population; PP population¼per-protocol population. The definitions of
both populations are provided in the section ‘Statistical methods and analysis’. The patient flow in both populations is depicted in Figure 1.
aTwo patients were not eligible for the
assessment of response according to the protocol because they did not complete two cycles of therapy. One more patient could not be assigned a response category because of
insufficient staging.
bFour patients were not eligible for the assessment of response because they did not complete two cycles of therapy due to rapid deterioration of their
functional status. Results for the ITT analysis are provided in the text.
Table 2 Tumour response (WHO) (Miller et al, 1981) (ITT and PP populations)
BDC study GBC study
ITT population
Number (%) of evaluable
patients (n¼37)
PP population
Number (%) of evaluable
patients (n¼34)
ITT population
Number (%) of evaluable
patients (n¼35)
PP population
Number (%) of evaluable
patients (n¼31)
CR 0 (0) 0 (0) 0 (0) 0 (0)
PR 7 (19) 7 (20) 8 (23) 8 (26)
NC 20 (54) 20 (59) 16 (46) 16 (52)
PD 6 (16) 6 (18) 6 (17) 6 (19)
Not assessable 4 (11) 1 (3) 5 (14) 1 (3)
Overall response (CR+PR) 7 (19) 7 (20) 8 (23) 8 (26)
Disease control (CR+PR+NC) 27 (73) 27 (79) 24 (69) 24 (77)
Abbreviations: BDC¼bile duct cancer; CR¼complete response; GBC¼gallbladder cancer; ITT population¼intention-to-treat-population; NC¼no change; PD¼progressive
disease; PR¼partial response; PP population¼per-protocol-population (both populations have been defined in the text; see ‘Statistical methods and analysis’ section).
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Chemotherapy was administered as planned for 46.7% of
scheduled treatments, was delayed for 17.9%, required dose
reduction for 18.9% or required both deferral and dose reduction
for 13.4%. One patient discontinued study therapy because of
oxaliplatin-induced polyneuropathy. A total of 17 hospitalisations
occurred during and in the first 30 days after chemotherapy
in GBC patients. Among these, three were attributed to febrile
infections, among which two were febrile neutropenia.
DISCUSSION
On the basis of favourable results of studies using two-drug
combinations including gemcitabine, oxaliplatin and fluoro-
pyrimidines (instead of 5-FU) (Alberts et al, 2005; Knox et al,
2005; Nehls et al, 2008), our trials were conducted to establish the
efficacy and safety of the triplet GemFOx chemotherapy in patients
with BDC and GBC. Taken together, these multicentre phase II
studies, which include a total of 72 patients, represent one of the
largest published series evaluating a single combination chemo-
therapy regimen in BTC. In addition, follow-up (up to 60 months)
in this trial was longer than in most other studies. As results from
randomised studies of chemotherapy in BTC are limited to two
phase III trials (n¼54) (Rao et al, 2005; Valle et al, 2009) and a
small number of phase II trials (n¼22–86 patients) (Kornek et al,
2004; Ducreux et al, 2005; Rao et al, 2005; Ciuleanu et al, 2007),
treatment decisions in these tumours have to also consider the
results of single-arm trials.
Both BDC and GBC are a clinically heterogeneous group of
cancers. Increasing evidence that these differences are also seen at
the molecular levels (Jarnagin et al, 2006) lends further support to
the notion that ‘gallbladder cancer is a different disease that needs
individual trials’ (Gallardo et al, 2005). Despite their heterogeneity,
the majority of previously published trials include both BDC
and GBC. In contrast, we evaluated – for the first time – the same
combination chemotherapy regimen separately and with adequate
power in patients with BDC and GBC. Although our trials
are inevitably limited by the single-arm study design, they
provide important and new clinical information regarding the
efficacy and toxicity of the triplet chemotherapy combination
under investigation.
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Figure 2 Overall survival (Kaplan–Meier) for patients with gallbladder
cancer (n¼35) and bile duct cancer (n¼37) (ITT population). þ,
censored observations.
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Figure 3 Quality of life (QoL), as measured by the FACT-Hep global
score. Given are the individual (grey) and mean (black) global QoL scores
(with 95% confidence interval), as measured by the FACT-Hep ques-
tionnaire. High scores represent a high QoL with the maximum achievable
value being 180, the minimum value 0. Quality of life was evaluated at
baseline, before cycles 3–13 and at the final evaluation. Percentage values
within the figure give the fraction of questionnaires divided by the number of
patients still in the study at the respective time point.
Table 3 Most frequent grade III/IV adverse effects (NCI-CTC) observed in BDC and GBC trials
BDC GBC
Grade I Grade II Grade III Grade IV Grade I Grade II Grade III Grade IV
Haemoglobin 18 (47.4) 14 (36.8) 4 (10.5) 2 (5.3) 21 (58.3) 18 (50.0) 2 (5.6) 0 (0)
Leukocytes 21 (55.3) 17 (44.7) 15 (13.2) 0 (0) 26 (72.2) 15 (41.7) 2 (5.6) 1 (2.8)
Neutrophils/granulocytes 15 (39.5) 12 (31.6) 9 (23.7) 5 (13.2) 18 (50.0) 13 (36.1) 10 (27.8) 2 (5.6)
Platelets 21 (55.3) 11 (28.9) 3 (7.9) 4 (10.5) 16 (44.4) 15 (41.7) 10 (27.8) 3 (8.3)
Bilirubin 1 (2.6) 10 (26.3) 7 (18.4) 8 (21.1) 2 (5.6) 10 (27.8) 5 (13.9) 1 (2.8)
AST/ALT 29 (76.3) 16 (42.1) 9 (23.7) 0 (0) 27 (75.0) 10 (27.8) 2 (5.6) 0 (0)
Alkaline phosphatase 26 (68.4) 15 (39.5) 7 (18.4) 0 (0) 24 (66.7) 9 (25.0) 4 (11.1) 0 (0)
Nausea 27 (71.1) 12 (31.6) 1 (2.6) 0 (0) 28 (77.8) 16 (44.4) 3 (8.3) 0 (0)
Diarrhoea 15 (39.5) 2 (5.3) 2 (5.3) 0 (0) 13 (36.1) 6 (16.7) 0 (0) 0 (0)
Anorexia 23 (60.5) 7 (18.4) 6 (15.8) 2 (5.3) 29 (80.6) 16 (44.4) 8 (22.2) 1 (2.8)
Oedema 5 (13.2) 8 (21.1) 6 (15.8) 0 (0) 6 (16.7) 7 (19.4) 3 (8.3) 0 (0)
Dyspnea 3 (7.9) 3 (7.9) 3 (7.9) 1 (2.6) 3 (8.3) 5 (13.9) 3 (8.3) 2 (5.6)
Sensory neuropathy 24 (63.2) 10 (26.3) 3 (7.9) 0 (0) 26 (72.2) 19 (52.8) 7 (19.4) 0 (0)
Fatigue 18 (47.4) 27 (71.1) 3 (7.9) 1 (2.6) 21 (58.3) 24 (66.7) 5 (13.9) 1 (2.8)
Fever 11 (28.9) 12 (31.6) 2 (5.3) 0 (0) 9 (25.0) 10 (27.8) 3 (8.3) 0 (0)
Infection 6 (15.8) 11 (28.9) 3 (7.9) 0 (0) 5 (13.9) 13 (36.1) 3 (8.3) 0 (0)
Febrile neutropenia 0 (0) 0 (0) 1 (2.6) 0 (0) 0 (0) 0 (0) 2 (5.6) (0)
Abbreviations: ALT¼alanine amino transaminase; AST¼aspartate amino transaminase; BDC¼bile duct cancer; GBC¼gallbladder cancer. Absolute (and relative, in %) number
of patients.
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and the median overall survival of 10 months compare favourably
with the results obtained with single-agent 5-FU or gemcitabine
(Ducreux et al, 2005; Valle et al, 2009), the hypothesis that
GemFOx might further improve on the results achieved with
modern two-drug combinations (Andre ´ et al, 2004, 2008; Alberts
et al, 2005; Knox et al, 2005; Kim et al, 2006) was not confirmed.
Nehls et al (2008) recently observed that adenocarcinoma
of extrahepatic bile ducts, including Klatskin’s tumours of the
liver hilus, seems to have a better prognosis and response to
chemotherapy than does intrahepatic cholangiocarcinoma.
Furthermore, a differential expression of molecular targets such
as HER-2 has been shown recently in intrahepatic and extrahepatic
BDC (Yoshikawa et al, 2008). Therefore, possible variations in the
relative proportions of intrahepatic and extrahepatic BDC might be
a confounding factor in previously published studies, rendering
conclusions regarding the efficacy of particular chemotherapy
regimens difficult. Although we had insufficient data to retro-
spectively stratify our patients with respect to BDC subtype, and
sound published epidemiological data are lacking, an unpublished
retrospective 3-year (1 January 2006 to 31 December 2008)
histopathological series of 839 unselected, consecutive cases of
BDC in Germany suggests that B70% of these tumours are
adenocarcinomas of the extrahepatic bile ducts (A Tannapfel,
personal communication, January 2009). Future studies should
address and clarify this issue by prospectively stratifying for the
intrahepatic and extrahepatic type of BDC.
For GBC, owing to the even more limited data, the question of
whether our triplet chemotherapy combination is superior to the
single-agent or two-drug combination regimens tested in previous
trials is more difficult to answer. Only 12 single-arm phase II and
no phase III studies in patients with GBC were identified in
a recent systematic search (Eckel and Schmid, 2007). Separate
results for GBC were reported in 18 further studies with a mixed
BTC population (F Eckel, personal communication, April 2008).
We updated this search in October 2008 and identified only one
additional abstract describing a prospective chemotherapy trial in
GBC (Gallardo et al, 2008). Overall survival in the larger series
(X40 patients) was 5.7 (Chatni et al, 2008), 7.0 (Reyes-Vidal et al,
2003), 7.4 (Misra et al, 2005) and 9.0 months (Gallardo et al, 2008).
Published results for GBC of all multicentre series, which included
more than 20 patients, are available as Supplementary Online
Material. Compared with these series, the median overall survival
of 9.9 months and 1-year overall survival rate of 36% observed
in our trial are encouraging. However, these results require
confirmation in a randomised study.
Intensified chemotherapy using a three-drug combination might
eventually allow for secondary resection of initially unresectable
disease. In fact, none of the patients in our trials qualified for
secondary resection, and we consider it unlikely that other
currently available chemotherapy combinations will perform
better. Thus, achieving secondary resectability appears to be an
unrealistic goal for chemotherapy regimens available at present in
patients with BTC.
The second major goal of our trials was to define the toxicity of
this triplet chemotherapy in the two patient populations: Overall,
the toxicity of the GemFOx combination chemotherapy in both
patient populations was manageable. However, as expected, the
rates of grade III and IV neutropenia (36.9 and 33.4% in patients
with BDC and GBC), thrombopenia (18.4 and 36.1% in BDC and
GBC) and anorexia (21 and 25.0% in BDC and GBC) in our study
were increased when compared with the recently presented data
for the gemcitabine/cisplatin combination in BTC (grade III/IV
neutropenia 22.6%, thrombopenia 8.2% and anorexia 1.9%) (Valle
et al, 2009). However, events such as febrile neutropenia (2.6 and
5.6% in BDC and GBC, respectively) or grade III/IV bleeding were
low, and there were no treatment-related deaths. As expected, the
risk of cholangitis was more important in patients with BDC
compared with those with GBC. In contrast to our trial in
pancreatic cancer (Wagner et al, 2007), the incidence of
cardiovascular events was unremarkable.
In conclusion, a GemFOx triplet chemotherapy regimen is
feasible in patients with advanced BTC, although the toxicity is
increased compared with doublets. Although for patients with BDC
the response rates and median overall survival in our trial do not
exceed the results reported for the use of chemotherapy doublets,
median overall survival for GBC compares favourably with most
other published trials. However, the number of patients included
in this trial is too small to draw definitive conclusions about the
balance between benefit and toxicity of this three-drug combina-
tion chemotherapy regimen in BTC. Future drug development in
BTC must account for the heterogeneity of BTC. The evolving
understanding of the biology of these tumours confirms the
existence of differences between GBC, as well as intrahepatic and
extrahepatic BDC, at the molecular level. More importantly, it
provides a basis for the rational use of targeted therapies that are
currently under clinical evaluation. Whether tumour response is
an appropriate primary end point for future clinical trials in biliary
neoplasms is still open to question (Gores et al, 2004). Overall
survival and patient-reported QoL have the advantage of being
direct indicators of patient benefit.
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